Chronic obstructive pulmonary disease: Histopathology, inflammation and potential therapies

Pulmonary Pharmacology and Therapeutics

Volumn 20, Issue 5, 2007, Pages 462-472

  Molfino, Néstor A ^a   Jeffery, Peter K ^b  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Anti inflammatory therapies; Chronic obstructive pulmonary disease; COPD; GOLD classification; Inflammatory immune response; Pathogenesis; Phosphodiesterase; Small airway obstruction

Indexed keywords

AMELUBANT; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CGP 2466; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CORTICOSTEROID; CS 003; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; DNK 333; GLUCOCORTICOID; I KAPPA B; IMIDAZOLE DERIVATIVE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR STIMULATING AGENT; LTB 019; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCLONAL ANTIBODY; NCX 950; OC 229648; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN INHIBITOR; ROFLUMILAST; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; SALBUTAMOL; SB 332235; STEROID; TACHYKININ RECEPTOR AGONIST; TETOMILAST; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; ASTHMA; BRONCHIOLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LUNG PARENCHYMA; MACROPHAGE; NAUSEA AND VOMITING; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 34447530157     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.04.003     Document Type: Article

References (103)

1. Lopez A.D., and Murray C.C. The global burden of disease, 1990-2020. Nat Med 4 11 (1998) 1241-1243
2. Mannino D.M. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 121 Suppl 5 (2002) 121S-126S
3. Molfino N.A. Drugs in clinical development for chronic obstructive pulmonary disease. Respiration 72 1 (2005) 105-112
4. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 6 (2004) 932-946
5. Jeffery P.K. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 53 2 (1998) 129-136
6. Urboniene D., Sakalauskas R., and Sitkauskiene B. Autoimmunity in pathogenesis of chronic obstructive pulmonary disease. Medicina (Kaunas) 41 3 (2005) 190-195
7. Cosio M.G., Majo J., and Cosio M.G. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest 121 Suppl 5 (2002) 160S-165S
8. Molfino N.A. Genetics of COPD. Chest 125 5 (2004) 1929-1940
9. Sethi S. New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis 17 2 (2004) 113-119
10. Yanai M., Sekizawa K., Ohrui T., et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol 72 3 (1992) 1016-1023
11. Pauwels R.A., Buist A.S., Ma P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 46 8 (2001) 798-825
12. Barnes P.J. New concepts in chronic obstructive pulmonary disease. Ann Rev Med 54 (2003) 113-129
13. Barnes P.J. Chronic obstructive pulmonary disease*12: new treatments for COPD. Thorax 58 9 (2003) 803-808
14. Jeffery P.K. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 164 10 Pt 2 (2001) S28-S38
15. Saetta M., Ghezzo H., Kim W.D., et al. Loss of alveolar attachments in smokers. A morphometric correlate of lung function impairment. Am Rev Respir Dis 132 4 (1985) 894-900
16. Rutgers S.R., Timens W., Kaufmann H.F., et al. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 15 1 (2000) 109-115
17. Verhoeven G.T., Hegmans J.P., Mulder P.G., et al. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax 57 8 (2002) 694-700
18. Jones J.G., Minty B.D., Lawler P., et al. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1 8159 (1980) 66-68
19. + T lymphocytes with FEV1. Am J Respir Crit Care Med 155 3 (1997) 852-857
20. + T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 3 Pt 1 (1998) 822-826
21. Hogg J.C., Chu F., Utokaparch S., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350 26 (2004) 2645-2653
22. Lams B.E., Sousa A.R., Rees P.J., et al. Subepithelial immunopathology of the large airways in smokers with and without chronic obstructive pulmonary disease. Eur Respir J 15 3 (2000) 512-516
23. +ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 2 (1999) 711-717
24. Di Stefano A., Capelli A., Lusuardi M., et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 158 4 (1998) 1277-1285
25. Maus U., Huwe J., Ermert L., et al. Molecular pathways of monocyte emigration into the alveolar air space of intact mice. Am J Respir Crit Care Med 165 1 (2002) 95-100
26. Wagner J.G., and Roth R.A. Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature. Pharmacol Rev 52 3 (2000) 349-374
27. Aldonyte R., Jansson L., Piitulainen E., et al. Circulating monocytes from healthy individuals and COPD patients. Respir Res 4 1 (2003) 11
28. Qiu Y., Zhu J., Bandi V., et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 168 8 (2003) 968-975
29. Saetta M., Baraldo S., and Zuin R. Neutrophil chemokines in severe exacerbations of chronic obstructive pulmonary disease: fatal chemo-attraction?. Am J Respir Crit Care Med 168 8 (2003) 911-913
30. Stockley R.A. Neutrophils and the pathogenesis of COPD. Chest 121 Suppl 5 (2002) 151S-155S
31. Nadel J.A. Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies. Chest 117 90052 (2000) 386S-389S
32. Thompson A.B., Huerta G., Robbins R.A., et al. The bronchitis index. A semiquantitative visual scale for the assessment of airways inflammation. Chest 103 5 (1993) 1482-1488
33. Thompson A.B., and Rennard S.I. Assessment of airways inflammation in chronic bronchitis. Eur Respir J 6 4 (1993) 461-464
34. Knowles M.R., and Boucher R.C. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 109 5 (2002) 571-577
35. Barnes P.J. Small airways in COPD. N Engl J Med 350 26 (2004) 2635-2637
36. Bosken C.H., Wiggs B.R., Pare P.D., et al. Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis 142 3 (1990) 563-570
37. Finkelstein R., Ma H.D., Ghezzo H., et al. Morphometry of small airways in smokers and its relationship to emphysema type and hyperresponsiveness. Am J Respir Crit Care Med 152 1 (1995) 267-276
38. Gosman M.M., Willemse B.W., Jansen D.F., et al. Increased number of B-cells in bronchial biopsies in COPD. Eur Respir J 27 1 (2006) 60-64
39. Retamales I., Elliott W.M., Meshi B., et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 164 3 (2001) 469-473
40. Majo J., Ghezzo H., and Cosio M.G. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 17 5 (2001) 946-953
41. Tsoumakidou M., Tzanakis N., and Siafakas N.M. Induced sputum in the investigation of airway inflammation of COPD. Respir Med 97 8 (2003) 863-871
42. Kharitonov S.A., and Barnes P.J. Exhaled markers of inflammation. Curr Opin Allergy Clin Immunol 1 3 (2001) 217-224
43. Carpagnano G.E., Kharitonov S.A., Foschino-Barbaro M.P., et al. Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. Eur Respir J 21 4 (2003) 589-593
44. Antczak A., and Gorski P. Markers of pulmonary diseases in exhaled breath condensate. Int J Occup Med Environ Health 15 4 (2002) 317-323
45. Santos S., Peinado V.I., Ramirez J., et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 19 4 (2002) 632-638
46. + T-lymphocytes in the paratracheal lymph nodes of smokers with mild COPD. Sarcoidosis Vasc Diffuse Lung Dis 20 1 (2003) 28-32
47. Wouters E.F. Introduction: systemic effects in chronic obstructive pulmonary disease. Eur Respir J Suppl 46 (2003) 1s
48. Oudijk E.J., Lammers J.W., and Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl 46 (2003) 5s-13s
49. Agusti A.G., Sauleda J., Miralles C., et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166 4 (2002) 485-489
50. Agusti A., Morla M., Sauleda J., et al. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 59 6 (2004) 483-487
51. Gosker H.R., Kubat B., Schaart G., et al. Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J 22 2 (2003) 280-285
52. Gosker H.R., Bast A., Haenen G.R., et al. Altered antioxidant status in peripheral skeletal muscle of patients with COPD. Respir Med 99 1 (2005) 118-125
53. Saetta M., Di Stefano A., Maestrelli P., et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 150 6 Pt 1 (1994) 1646-1652
54. Zhu J., Qiu YS., Majumdar S., Gamble E., Matin D., Urato G., et al. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 164 (2001) 109-116
55. Emerman C.L., Connors A.F., Lukens T.W., et al. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest 95 3 (1989) 563-567
56. Jeffery P.K. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest 117 5 Suppl 1 (2000) 251S-260S
57. Cox G., Whitehead L., Dolovich M., et al. A randomized controlled trial on the effect of inhaled corticosteroids on airways inflammation in adult cigarette smokers. Chest 115 5 (1999) 1271-1277
58. Drost E.M., Skwarski K.M., Sauleda J., et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 60 4 (2005) 293-300
59. Cox G., Whitehead L., Dolovich M., et al. A randomized controlled trial on the effect of inhaled corticosteroids on airways inflammation in adult cigarette smokers. Chest 115 5 (1999) 1271-1277
60. Caramori G., and Adcock I. Pharmacology of airway inflammation in asthma and COPD. Pulm Pharmacol Ther 16 5 (2003) 247-277
61. Hattotuwa K.L., Gizycki M.J., Ansari T.W., et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 165 12 (2002) 1592-1596
62. Wood-Baker R. Is there a role for systemic corticosteroids in the management of stable chronic obstructive pulmonary disease?. Am J Respir Med 2 6 (2003) 451-458
63. Gizycki M.J., Hattotuwa K.L., Barnes N., et al. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 57 9 (2002) 799-803
64. Keatings V.M., Collins P.D., Scott D.M., et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153 2 (1996) 530-534
65. Barnes P.J., Adcock I.M., and Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 25 3 (2005) 552-563
66. Sin D.D., Wu L., Anderson J.A., et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60 12 (2005) 992-997
67. Soriano J.B., Kiri V.A., Pride N.B., et al. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2 1 (2003) 67-74
68. Barnes N.C., Qiu Y.S., Pavord I.D., et al. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173 (2006) 736-743
69. Barnes P.J. Cyclic nucleotides and phosphodiesterases and airway function. Eur Respir J 8 3 (1995) 457-462
70. Gamble E., Grootendorst D.C., Brightling C.E., et al. Anti-inflammatory effects of the phosphodiesterase 4 inhibitor cilomilast (Ariflo) in COPD. Am J Respir Crit Care Med 168 (2003) 976-982
71. Giembycz M.A. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?. Drugs 59 2 (2000) 193-212
72. Schudt C., Gantner F., Tenors H., et al. Therapeutic potential of selective PDE inhibitors in asthma. Pulm Pharmacol Ther 12 2 (1999) 123-129
73. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157 2 (1998) 351-370
74. Compton C.H., Gubb J., Nieman R., et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358 9278 (2001) 265-270
75. Rabe K.F., Bateman E.D., O'Donnell D., et al. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trail. Lancet 366 9485 (2005) 563-571
76. Chihiro M., Nagamoto H., Takemura I., et al. Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: synthesis and structure-activity relationships. J Med Chem 38 2 (1995) 353-358
77. Nagamoto H., Kawasome H., Sueyoshi S., et al. OPC-6535, a novel thiazole compound, inhibits neutrophil adhesion to endothelial cells in vitro. Am J Respir Crit Care Med 169 (2004) A572
78. Nagamoto H., Haruta J., Miyakoda G., et al. The effects of OPC-6535, a novel thiazole compound, on the production of cytokines in human peripheral blood mononuclear cells in vitro. Am J Respir Crit Care Med 169;A572 (2004)
79. Nagamoto H., Ohta K., Ikezono K., et al. The effect of OPC-6535, a novel inhibitor of leukocyte activation on airway inflammation in a guinea pig model of COPD induced by cigarette smoke. Proc Am Thorac Soc 2 (2005) A127
80. Wise RA, Littner MR, Zhang P, et al. Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD). Eur Respir J 2006; abstract (in press).
81. MacNee W. Oxidants/antioxidants and COPD. Chest 117 5 Suppl 1 (2000) 303S-317S
82. MacNee W. Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy. Novartis Found Symp 234 (2001) 169-185
83. MacNee W., and Rahman I. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease?. Trends Mol Med 7 2 (2001) 55-62
84. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 429 1-3 (2001) 195-207
85. Decramer M., Rutten-van Molken M., Dekhuijzen P.N., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365 9470 (2005) 1552-1560
86. Bonn D. Tackling the real culprits in Crohn's disease. Lancet 351 9117 (1998) 1710
87. Maestrelli P., Paska C., Saetta M., et al. Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients. Eur Respir J 21 6 (2003) 971-976
88. Rutgers S.R., van der Mark T.W., Coers W., et al. Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax 54 7 (1999) 576-580
89. van Straaten J.F., Postma D.S., Coers W., et al. Macrophages in lung tissue from patients with pulmonary emphysema express both inducible and endothelial nitric oxide synthase. Mod Pathol 11 7 (1998) 648-655
90. Hansel T.T., Kharitonov S.A., Donnelly L.E., et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J 17 10 (2003) 1298-1300
91. Dugo L., Marzocco S., Mazzon E., et al. Effects of GW274150 a novel and selective inhibitor of iNOS activity, in acute lung inflammation. Br J Pharmacol 141 6 (2004) 979-987
92. Lagente V., Naline E., Guenon I., et al. A nitric oxide-releasing salbutamol elicits potent relaxant and anti-inflammatory activities. J Pharmacol Exp Ther 310 1 (2004) 367-375
93. Nevin B.J., and Broadley K.J. Comparative effects of inhaled budesonide and the NO-donating budesonide derivative, NCX 1020, against leukocyte influx and airway hyperreactivity following lipopolysaccharide challenge. Pulm Pharmacol Ther 17 4 (2004) 219-232
94. Aeberli D., Oertle S., Mauron H., et al. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 132 29-30 (2002) 414-422
95. Blanchard C., Mishra A., Saito-Akei H., et al. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy 35 8 (2005) 1096-1103
96. Holtmann M.M. RDP-58 (SangStat Medical). IDrugs 6 12 (2003) 1188-1194
97. Stevenson C.S., Coote K., Webster R., et al. Characterization of cigarette smoke-induced inflammatory and mucus hypersecretory changes in rat lung and the role of CXCR2 ligands in mediating this effect. Am J Physiol Lung Cell Mol Physiol 288 3 (2005) L514-L522
98. Trifilieff A., Wyss D., Walker C., et al. Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities. J Pharmacol Exp Ther 301 1 (2002) 241-248
99. Romano S.J., and Slee D.H. Targeting selectins for the treatment of respiratory diseases. Curr Opin Investig Drugs 2 7 (2001) 907-913
100. Chung K.F. Current and future prospects for drugs to suppress cough. IDrugs 6 8 (2003) 781-786
101. Joos G.F., and Pauwels R.A. Tachykinin receptor antagonists: potential in airways diseases. Curr Opin Pharmacol 1 3 (2001) 235-241
102. Birke F.W., Meade C.J., Anderskewitz R., et al. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther 297 1 (2001) 458-466
103. Gronke L, Beeh KM. LTB 019 A, a leukotriene B(4) receptor antagonist, has no effect on the levels of neutrophils, MPO, IL-8 and TNF-alpha in induced sputum of patients with COPD. Am J Resp Crit Care Med 165[2], 598. 4-20-0002.